Status:
COMPLETED
China Betaferon Adherence, Coping and Nurse Support Study
Lead Sponsor:
Bayer
Conditions:
Multiple Sclerosis, Chronic Progressive
Eligibility:
All Genders
18-75 years
Brief Summary
Non-adherence reduces treatment benefit and can bias the assessment of treatment efficacy thereby involving safety risks for the patient and influencing health cost-effectiveness. This observational s...
Eligibility Criteria
Inclusion
- Relapsing-remitting multiple scelrosis (RRMS) and secondary progressive multiple sclerosis (SPMS) patients
- Having Betaferon treatment, including patients who are
- First time using; or
- Re-staring; or
- Switching from other diseases modifying drugs (DMDs)
Exclusion
- Known or newly identified contraindication for administration of Betaferon according to Summary of Product Characteristic (SmPC).
Key Trial Info
Start Date :
March 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT01436838
Start Date
March 1 2012
End Date
December 1 2015
Last Update
September 5 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, China